Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023 17:30 ET
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023 08:05 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 15, 2023 08:25 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022 16:01 ET
|
Coherus BioSciences, Inc.
– UDENYCA® net sales of $45.4 million in the third quarter 2022 –– CIMERLI™ launched in the United States on October 3rd –– Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and...
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
July 06, 2022 08:00 ET
|
Coherus BioSciences, Inc.
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY,...
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
May 02, 2022 07:00 ET
|
Coherus BioSciences, Inc.
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - -...
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
April 14, 2022 08:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”,...
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
April 08, 2022 13:10 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
March 29, 2022 09:15 ET
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
March 15, 2022 08:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical...